Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

Table 2 Risk indices (n = 780)

	Group A Bridging n = 111	Group B VKA n = 318	Group C DOAC n = 351	p-value A-B	p-value A-C	p-value B-C
CHA₂DS₂VASc				0.441	0.176	0.431
0	10 (9.0)	33 (10.4)	57 (16.2)
1	34 (30.6)	112 (35.2)	121 (34.5)
2	38 (34.2)	82 (25.8)	90 (25.6)
3	16 (14.4)	57 (17.9)	51 (14.5)
4	11 (9.9)	24 (7.5)	22 (6.3)
5	1 (0.9)	9 (2.8)	9 (2.6)
6	1 (0.9)	1 (0.3)	1 (0.3)
HAS-BLED				0.903	0.006	0.001
0	14 (12.6)	40 (12.6)	85 (24.2)
1	47 (42.3)	117 (36.8)	156 (44.4)
2	33 (29.7)	109 (34.3)	80 (22.8)
3	14 (12.6)	43 (13.5)	29 (8.3)
4	3 (2.7)	8 (2.5)	1 (0.3)
5	0 (0.0)	1 (0.3)	0 (0.0)

Legend: Bridging interrupted vitamin-K-antagonist, CHA₂DS₂VASc cardiac failure or dysfunction, hypertension, age ≥ 75 [doubled], diabetes, stroke [doubled]-vascular disease, age 65–74, sex category [female]) score, DOAC uninterrupted non-vitamin-K anticoagulants, HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (> 65 years), drugs/alcohol concomitantly, VKA uninterrupted vitamin-K-antagonist

ISSN: 1471-2261